Alnylam Pushes Back Development of Flu Drug, Tweaks Other Pipeline Programs

During a conference call to discuss the company’s second-quarter financial results, Alnylam COO Barry Greene attributed the delay in the flu program partly to the government’s waning interest in “novel” pandemic flu treatments, but comments by President and CEO John Maraganore suggest that specificity issues are mostly to blame.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories